Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice
Vericiguat users initiated on the 5 mg/day dose were considerably more likely to reach the target dose of 10 mg/day vs. those started on the recommended 2.5 mg/day dose, without excess risk of hypotension or syncope.
Authors
- Coralie Lecomte (ORCID: https://orcid.org/0009-0007-0282-2939)
- Alexander Michel (ORCID: https://orcid.org/0000-0002-8107-5818)
- Katsiaryna Holl
- Paolo Manca
- Michele Senni
- Stephen J. Greene
Institutions
- Clinical Research Institute (US)
- Ospedale Papa Giovanni XXIII (IT)
- Aetion (United States) (US)
- Bayer (Switzerland) (CH)
- Bayer (Italy) (IT)
- Duke Medical Center (US)
- Bayer (Germany) (DE)
Publication Details
- Journal
- American Heart Journal Plus Cardiology Research and Practice
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1016/j.ahjo.2026.100721
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00